VivoSeq
Oncology

Recurrent B-Cell Non-Hodgkin Lymphoma

10

Pipeline Programs↗

3

Active Trials↗

9

Companies Involved↗

Recurrent B-Cell Non-Hodgkin Lymphoma is an early-stage landscape with 10 programs across 9 companies. The most active players are Takeda, Roche, Gilead.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

6/100

Mech. Concentration

13/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

1 program

Phase 1Roche logo

Roche

1 program

Phase 1Gilead logo

Gilead

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2Genmab logo

Genmab

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

64%

Small molecule

7 of 11 classified programs — the dominant modality here.

36%ALL OTHERSMonoclonal antibody327%Cell therapy19%

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.

Analysis

Trial Status

4

clinical trials

Active, not recruiting2 · 50%
Recruiting1 · 25%
Completed1 · 25%

Clinical Trials

Trial Activity

A Phase II Study of Combination Epcoritamab-Lenalidomide in Patients With Refractory/Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
Recruiting·NNorthwestern University·Phase 2·NCT06723457·34 enrolled
A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma
Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT01695941·24 enrolled
A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma (NHL)
Completed·MMayo Clinic·Phase 2·NCT02332980·65 enrolled
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Active, not recruiting·FFred Hutchinson Cancer Center·Preclinical·NCT03277729·53 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)